An oral formulation of an antiangiogenic drug may allow long-term anti-cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Benny, O. Nat. Biotechnol. 26, 799–807 (2008).
Folkman, J. N. Engl. J. Med. 285, 1182–1186 (1971).
Hanahan, D. & Folkman, J. Cell 86, 353–364 (1996).
Folkman, J. Nat. Rev. Drug Discov. 6, 273–286 (2007).
Jain, R.K., Duda, D.G., Clark, J.W. & Loeffler, J.S. Nat. Clin. Pract. Oncol. 3, 24–40 (2006).
Gasparini, G., Longo, R., Fanelli, M. & Teicher, B.A. J. Clin. Oncol. 23, 1295–1311 (2005).
Thurston, G., Noguera-Troise, I. & Yancopoulos, G.D. Nat. Rev. Cancer 7, 327–331 (2007).
Ingber, D. et al. Nature 348, 555–557 (1990).
Bhargava, P. et al. Clin. Cancer Res. 5, 1989–1995 (1999).
Satchi-Fainaro, R. et al. Nat. Med. 10, 255–261 (2004).
Ferrara, N. & Kerbel, R.S. Nature 438, 967–974 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
James, D., Rabbany, S. & Rafii, S. Hitting the mother lode of tumor angiogenesis. Nat Biotechnol 26, 769–770 (2008). https://doi.org/10.1038/nbt0708-769
Issue Date:
DOI: https://doi.org/10.1038/nbt0708-769